ALPN - Alpine Immune Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

6.18

-0.27 (-4.19%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	6.45
Open	6.42
Bid	0.00 x 2200
Ask	0.00 x 1300
Day's Range	6.18 - 6.50
52 Week Range	5.28 - 12.87
Volume	23,242
Avg. Volume	15,759

Market Cap	85.598M
Beta	0.27
PE Ratio (TTM)	N/A
EPS (TTM)	-1.18
Earnings Date	Nov 12, 2018 - Nov 16, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	14.00

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wirelast month
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the second quarter ended June 30, 2018.
Business Wire2 months ago
Alpine Immune Sciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Alpine Immune Sciences, Inc. (ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton, Ph.D., Alpine’s new President and Chief Operating Officer, effective August 6, 2018. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD technology, to potentially enhance engineered cellular therapies.
American City Business Journals2 months ago
Alpine Immune Sciences hires Alder co-founder as president and operations chief
Alder Biopharmaceuticals, the Puget Sound region's third-largest biotech, has lost two of its three founders in the last six months and hired new leaders.
Business Wire2 months ago
Alpine Immune Sciences to Present at 2018 Wedbush PacGrow Healthcare Conference
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 3:40 pm Eastern Time in New York, NY.
Business Wire2 months ago
Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating Officer
Alpine Immune Sciences, Inc. (ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today announced the appointment of life sciences veteran Mark Litton, Ph.D. to the role of President and Chief Operating Officer. Dr. Litton joins Alpine from Alder BioPharmaceuticals, where he has served as Chief Business Officer and Treasurer since co-founding the company in 2004. “We are excited for Mark to take on this key leadership role during a pivotal time for Alpine as we work to drive our two lead programs toward the clinic,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine.
Business Wire2 months ago
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zhejiang China, today announced the completion of the sale and transfer of global rights to the S-Nitrosoglutathione Reductase ...
Business Wire4 months ago
Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5 2018 at 4:30 pm Eastern Time in New York, NY.
Benzinga4 months ago
Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation
Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN ), as the biotech 's initial candidates will enter the clinic over the next year. The Analyst Robert Driscoll ...
Business Wire4 months ago
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2018.
Business Wire5 months ago
Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors
Alpine Immune Sciences, Inc. announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics.
Business Wire5 months ago
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today presented preclinical study results of its ALPN-202 immuno-oncology program.
ACCESSWIRE5 months ago
Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program
Stock Monitor: Alpine Immune Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on ImmunoCellular Therapeutics, Ltd ...
Business Wire6 months ago
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results
Alpine Immune Sciences, Inc. , a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory diseases, today provided a corporate update and reported financial results for the year ended December 31, 2017.
Business Wire6 months ago
Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer Research Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.
Business Wire7 months ago
Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at the Cowen 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 4:10 pm Eastern Time.
Business Wire9 months ago
Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results from a preclinical study of the company’s ALPN-101 program in a humanized model of graft vs.
Business Wire10 months ago
Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a preclinical study of novel immuno-oncology molecules derived from the company’s variant immunoglobulin domain platform.
Business Wire10 months ago
Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.
Business Wire10 months ago
Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced immuno-oncology preclinical data characterizing the functional activity of molecules Alpine successfully generated from its variant immunoglobulin domain platform.
Business Wire11 months ago
Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced results from preclinical studies evaluating ALPN-101 program dual ICOS/CD28 antagonists generated by the company’s variant immunoglobulin domain platform.
Business Wire11 months ago
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a Gilead company.
Business Wire11 months ago
Alpine Immune Sciences Announces Upcoming Scientific Presentations
Alpine Immune Sciences, Inc. , a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced planne